Day: June 20, 2022
SHANGHAI, China, June 20, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced the appointment of Donna Ambrosino, M.D., and Ralf Clemens, M.D., Ph.D., to the company’s Board of Directors.
“We are pleased to welcome Donna and Ralf, who have been members of our Vaccine Scientific Advisory Board since 2020 and have been instrumental to the development of our lead COVID-19 vaccine candidate, to our Board of Directors and look forward to their additional contributions to our overall corporate strategy and governance,” said Joshua Liang, Chief Executive Officer and Executive Director of Clover. “Donna’s background as a celebrated researcher, infectious disease expert, and proven biotech...